Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
The nanoparticle-scope : a new integrated instrument for accurate and reproducible physico-chemical characterisation of nanoparticles (npSCOPE) (npSCOPE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Ensuring the safe and sustainable development and application of nanotechnologies
Action type: Research and Innovation actions
Countries involved: Germany,Germany,Germany,Germany,Switzerland,Belgium,France,Netherlands,United States,Luxembourg
Call: Analytical techniques and tools in support of nanomaterial risk assessment (H2020-NMBP-2016-two-stage, 2016)
Start date: 2017-01-01
End date: 2021-06-30
Duration (months): 54.0
Total project cost (EUR): 7487475.0
EU funding (EUR): 6661600.0
Participants: 11
Project status: CLOSED

The npSCOPE project aims at developing a new integrated instrument (the nanoparticle-scope) optimised for providing a complete physico-chemical characterisation of nanoparticles both in their pristine form or embedded in complex matrices such as biological tissues. Using sophisticated correlative data processing methodologies and algorithms based on statistical methods in conjunction with appropriate visualisation methods of the results, the npSCOPE instrument will allow rapid, accurate and reproducible measurements. The instrument will be based on the Gas Field Ion Source as a key enabling technology, which we will combine with a number of new developments in the field of electron and ion microscopy. We will progressively ramp up the TRL of the instrument and associated methodologies to reach TRL 7 by the end of the project. The new technology, and all related processes and methodologies, will be validated via round-robin studies performed independently by several partner institutions, crosschecked with conventional analysis technologies to demonstrate the advancements and capabilities of the npSCOPE technology and benchmarked in representative case studies. Given the low sample quantities needed and the strong potential of the instrument to generate high-quality physico-chemical data on nanomaterials, both ex situ and in situ, npSCOPE will allow a major step forward in defining key descriptors for read-across, grouping, in silico modelling and creating meaningful relationships with biological activity data for QSAR purposes. To reach these objectives, the project consortium will be composed of research centres internationally recognised for innovative instrument developments, well-established instrument manufacturers and experts in nanotoxicology in various fields of application to demonstrate and validate the applicability of npSCOPE for the risk assessment of nanomaterials in consumer products.

Keywords: instrument development,helium ion beam,high resolution,high sensitivity,correlative methodologies,rapid data processing,complex matrices,biological samples,nanotoxicology
Innovation Networks of Cork, Resins and Edibles in the Mediterranean basin (INCREdible)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Sustainable and competitive agri-food sector for a safe and healthy diet
Action type: Coordination and support actions
Countries involved: Italy,Spain,Spain,Spain,Italy,Greece,Tunisia,Croatia,Belgium,Finland,France,Portugal
Call: Thematic Networks compiling knowledge ready for practice (H2020-RUR-2017-1, 2017)
Start date: 2017-11-01
End date: 2021-04-30
Duration (months): 42.0
Total project cost (EUR): 1999150.0
EU funding (EUR): 1999150.0
Participants: 14
Project status: CLOSED

Mediterranean forests play a pivotal role for local economies by providing a large array of ecosystem services and goods. Despite its potential, the sector is facing significant challenges at many levels, including: low profitability of slow-growing timber, niche markets for Non-Wood Forest Products (NWFPs), and a wider context of aging rural population, farmland abandonment and scrub encroachment, leading to an increase in the occurrence of megafires, which is further aggravated by climate change. A sustainable, inclusive, smart bio-based economy centred on multipurpose trees and NWFPs can be part of the solution, if triggered by an improvement in knowledge exchange channels between NWFP practitioners and scientists, and among regions. The purpose of INCREdible is to address the existing research and innovation knowledge divide in relation to NWFP-service systems of the Mediterranean basin. In particular, INCREdible aims to link knowledge and foster collaboration among different groups of stakeholders, developing innovative business models and enhancing the expertise of rural regions towards the development of inclusive economic strategies. To achieve these objectives, INCREdible will developan Innovation NETworks (iNets) around crucial lines of Mediterranean NWFPs: cork, resins, aromatics, and edibles. Each iNet will aim to gather best practices (both practical and science-based) related to NWFP production, transformation and trade channels. Particular attention will be drawn to cross-cutting sectorial issues such as: (i) innovative business models and value chains, (ii) innovative access to finance, (iii) innovative marketing and digital tools. Lastly, INCREdible will collect information and knowledge arising from iNets into an interregional online platform, which will function both as deposit and exchange system of information among partners, existing networks and organizations, for raising awareness of existing success cases and cross-fertilization.

Keywords: open innovation,non wood forest products,multi actor approach,social and participatory innovation
Magnetomechanical Platforms for Quantum Experiments and Quantum Enabled Sensing Technologies (MaQSens)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Research and Innovation actions
Countries involved: Spain,Austria,Germany
Call: FET-Open research and innovation actions (H2020-FETOPEN-1-2016-2017, 2016)
Start date: 2017-01-01
End date: 2021-03-31
Duration (months): 51.0
Total project cost (EUR): 3082755.0
EU funding (EUR): 2699369.09
Participants: 4
Project status: CLOSED

This project seeks to establish a radically new technology platform for experiments in macroscopic quantum physics and for quantum enabled sensing. We exploit magnetic coupling between superconducting quantum circuits and superconducting mechanical resonators – both levitated and suspended – to enter a hitherto inaccessible parameter regime of both unprecedented force sensitivity and full quantum control of massive, macroscopic objects. Our approach combines, in a new way, techniques from different research areas (magnetic levitation, superconducting circuits, atom-chip technology, cavity optomechanics and quantum optics) and is set up as a joint collaborative effort between expert European teams from academia and industry. Our technology will enable quantum experiments of otherwise unachievable coherence times and masses, which has immediate implications for testing fundamental physical questions, for performing hybrid quantum information processing and, on the applied side, for ultrasensitive force sensing applications.

Keywords: quantum mechanics,quantum optomechanics,physics,micromechanics,superconducting,levitation,macroscopic quantum physics
IOT and cloud computing for online medical analysis service platform (DeltaQon)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-09-01
End date: 2020-02-29
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

DeltaQon is an online medical analysis service platform based on MovMe, an innovative prototype device that delivers high accuracy measurements of the movement of the human body through a portable and simple to use digital technology. The device produces a simple and objective measurement of a patient’s movements which can help to detect degenerative diseases caused by accidents or bad movements. In the past year fifty devices have been manufactured and delivered for initial trials. They are currently deployed at several clinics throughout Spain, in total we have 61 units in the market collecting data, this data is the basis of the online medical service platform: DeltaQon.

Keywords: cloud platform,digital technology,eu welfare
RESIlience enhancement and risk control platform for communication infraSTructure Operators (RESISTO)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure societies - protecting freedom and security of Europe and its citizens
Theme: Protect and improve the resilience of critical infrastructures, supply chains and tranport modes
Action type: Innovation actions
Countries involved: Germany,Italy,Spain,Italy,Germany,Spain,Estonia,Cyprus,Greece,Romania,Greece,Romania,United Kingdom,Portugal,Portugal
Call: Prevention, detection, response and mitigation of the combination of physical and cyber threats to the critical infrastructure of Europe. (CIP-2016-2017-2, 2017)
Start date: 2018-05-01
End date: 2021-10-31
Duration (months): 42.0
Total project cost (EUR): 10531803.71
EU funding (EUR): 7999970.0
Participants: 22
Project status: CLOSED

Communications play a fundamental role in the economic and social well-being of the citizens and on operations of most of the CIs. Thus they are a primary target for criminals having a multiplier effect on the power of attacks and providing enormous resonance and gains. Also extreme weather events and natural disasters represents a challenge due to their increase in frequency and intensity requiring smarter resilience of the Communication CIs, which are extremely vulnerable due to the ever-increasing complexity of the architecture also in light of the evolution towards 5G, the extensive use of programmable platforms and exponential growth of connected devices. The fact that most enterprises still manage physical and cyber security independently represents a further challenge. RESISTO platform is an innovative solution for Communication CIs holistic situation awareness and enhanced resilience (aligned with ECSO objectives). Based on an Integrated Risk and Resilience analysis management and improvement process availing all resilience cycle phases (prepare, prevent, detect, absorb, etc.) and technical resilience capabilities (sense, model, infer, act, adopt), RESISTO implements an innovative Decision Support System to protect communication infrastructures from combined cyber-physical threats exploiting the Software Defined Security model on a suite of state of the art cyber/physical security components (Blockchain, Machine Learning, IoT security, Airborne threat detection, holistic audio-video analytics) and services (Responsible Disclosure Framework) for detection and reaction in presence of attacks or natural disasters. Through RESISTO Communications Operators, will be able to implement a set of mitigation actions and countermeasures that significantly reduce the impact of negative events in terms of performance losses, social consequences, and cascading effects in particular by bouncing efficiently back to original and forward to operational states of operation.

Keywords: risk and resilience joint management,cyber and physical threads technological and operational collaboration,innovative monitoring detection prevention response mitigation,technologies and approaches
Beyond mass drug administration: understanding Schistosomiasis dynamics to STOP transmission (SchiSTOP)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Netherlands,Netherlands
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2021-05-03
End date: 2023-05-02
Duration (months): 24.0
Total project cost (EUR): 175572.48
EU funding (EUR): 175572.48
Participants: 2
Project status: SIGNED

Neglected tropical diseases (NTDs) are a diverse group of infections which are especially prevalent in low-income populations in tropical and subtropical areas in Africa, Asia and the Americas. Schistosomiasis is the deadliest NTD killing an estimated 280,000 people each year in the African region alone. The World Health Organization (WHO) 2020 target for schistosomiasis is to reduce the prevalence of heavy-intensity infections to ≤5% among school-aged children through Mass Drug Administration (MDA). However, in areas of moderate and high prevalence the goal seems unlikely to be met as even with intensive biannual MDA, prevalence of infections are still seen to rebound rapidly after each round. The reasons are still poorly understood. Mathematical models and statistical methods have proven to be essential to gain insights into the complex processes underlying the transmission dynamics of infectious diseases. In this research project, I will develop a stochastic individual-based model (IBM) to simulate schistosomiasis transmission integrating cutting-edge mathematical models and statistical methods with recent advances in parasite genetics, epidemiology, diagnostics and immunology. This project aims to advance our current understanding of schistosomiasis transmission dynamics investigating the mechanisms that cause the rapid rebound of prevalence after MDA and proposing optimal implementation of current and novel strategies to achieve schistosomiasis control and move towards elimination. In addition, this project will build a reference methodological framework to comprehensively study other MDA targeted infectious diseases. The proposed project addresses one of the priorities of the EU, through global poverty reduction (SDG goal 1) by promoting ways of improving future health (SDG goal 3).This project will be carried out at Erasmus MC with Prof. Sake J. de Vlas and at University of Glasgow (secondment) with Dr. Poppy Lamberton.

Keywords: neglected tropical diseases,schistosomiasis,infectious disease epidemiology,mathematical modelling,bayesian biostatistics
Novel Gene Therapy Based on the Activation of Endogenous Genes for the Treatment of Ischemia - Concepts of endogenetherapy, release of promoter pausing, promoter-targeted ncRNAs and nuclear RNAi (CleverGenes)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: Finland
Call: ERC Advanced Grant (ERC-2014-ADG, 2014)
Start date: 2015-11-01
End date: 2021-04-30
Duration (months): 66.0
Total project cost (EUR): 2437500.0
EU funding (EUR): 2437500.0
Participants: 1
Project status: CLOSED

Background: Therapeutic angiogenesis with vascular endothelial growth factors (VEGFs) has great potential to become a novel, minimally invasive new treatment for a large number of patients with severe myocardial ischemia. However, this requires development of new technology. Advancing state-of-the-art: We propose a paradigm shift in gene therapy for chronic ischemia by activating endogenous VEGF-A,-B and -C genes and angiogenic transcription programs from the native promoters instead of gene transfer of exogenous cDNA to target tissues. We will develop a new platform technology (endogenetherapy) based on our novel concept of the release of promoter pausing and new promoter-targeted upregulating short hairpinRNAs, tissue-specific superenhancerRNAs activating specific transcription centers involving gene clusters in different chromosomal regions, small circularRNAs formed from self-splicing exons-introns that can be regulated with oligonucleotides and small molecules such as metabolites, nuclear RNAi vectors and specific CRISPR/gRNAmutatedCas9-VP16 technology with an ability to target integration into genomic safe harbor sites. After preclinical studies in mice and in a newly developed chronic cardiac ischemia model in pigs with special emphasis on the analysis of clinically relevant blood flow, metabolic and functional outcomes based on MRI, ultrasound, photoacoustic and PET imaging, the best construct will be taken to a phase I clinical study in patients with severe myocardial ischemia. Since endogenetherapy also involves epigenetic changes, which are reversible and long-lasting, we expect to efficiently activate natural angiogenic programs. Significance: If successful, this approach will begin a new era in gene therapy. Since there is a clear lack of technology capable of targeted upregulation of endogenous genes, the novel endogenetherapy approach may become widely applicable beyond cardiovascular diseases also in other areas of medicine and biomedical research.

Keywords: non coding rnas,cardiovascular diseases,vectors,angiogenesis,ischemia,vascular endothelial growth factors,promoter pausing,targeted integration,rnai,clinical trial
Enhancement of an advanced clinical trial recruitment platform for Europe to ensure maximum intake of eligible consenting patients for participation (CliniTrial)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Active ageing and self-management of health
Action type: SME instrument
Countries involved: Germany
Call: Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-11-01
End date: 2017-04-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Many patients can’t effectively be treated with the standard of care today. They suffer from their diseases that can’t be managed or cured. Newly developed therapies represent their only hope. Unfortunately, it takes ever more time and money to bring innovative therapies to market. A major challenge in clinical development is finding the right patients to participate in clinical trials. The problem is that patients lack access to trials. The online platform viomedo supports patients with finding the right clinical trial for them, while helping the organizations that run trials, such as pharmaceutical companies, recruit patients more efficiently. The disruptive solution provides access to over 2.000 up-to-date clinical trials that are recruiting patients in Germany. Patients, care givers or doctors can easily search for a trial by disease, confirm their eligibility and contact the investigator. Patients want to be increasingly involved in deciding which therapy to choose. 75% of them are interested in learning about clinical trial opportunities. Most turn mainly to the internet for health-related information. However, a patient-centric online platform for clinical trials is missing. Viomedo empowers patients by providing this platform. Important milestones – such as the development of a public beta version of the platform, collaboration with leading patient advocacy groups, acquisition of six large pilots with pharmaceutical companies – have been reached. The goal of phase 1 is to complete the pilot projects and develop an EU-wide rollout strategy. After the business case is ready and validated, viomedo will be rolled out to major European markets in phase 2. Once viomedo is rolled out to all European patients, it will help more patients benefit from the research earlier. It will also make the EU a more attractive region for conducting research. It will help bring patient centricity and openness into the industry, raising the quality of clinical research conducted.

Keywords: clinical trials,clinical development,online patient recruitment,investigator sites
A 3D advanced test for prediction of drug response in secondary liver cancer (SpheroPredict)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Germany
Call: Supporting innovative SMEs in the healthcare biotechnology sector (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2017-01-01
End date: 2017-04-30
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Cancer remains one of the deathliest diseases of the 21st century, with more than 1.9 M deaths per year in Europe. Some tumours entail a high risk of metastasizing, meaning that they are able to reach other locations in the body. Migrating cells from a primary tumour often cause secondary cancer in the liver, which is one of the leading causes of death worldwide.Regarding treatment options, international institutions have published clear guidelines about first line treatments to treat particular types of primary cancers. However, when dealing with secondary cancers (like metastatic liver cancer) there is a heterogeneous and very wide range of treatment options and no clear guidelines. The choice of treatment in secondary cancer is based in “trial and error”. This “trial and error” approach causes many patients fail to respond to therapy due to chemoresistance (lack of response to chemotherapy). In response, we at SpheroTec have created SpheroPredict, an individualised drug testing platform designed to predict the patient’s response to guideline therapies before installing the treatment cycle. Using cancer cells from the patient’s tumour, we build an accurate and biologically relevant 3D micro-tumour (spheroid) model to test the drugs and analyse the response in advance. In the end, only drugs with proven efficacy and low toxicity will be applied in the patient’s therapy cycle. In the era of personalised medicine and with the urgent need for de-risked and efficient drug treatments, we have developed an innovative solution that will greatly improve the patient’s survival time, quality of life and will help to alleviate the economic burden on the EU healthcare system incurred by inefficient therapies and productivity loss. Thus, in Phase 1, we aim to warrant the feasibility of the SpheroPredict project from the technical, commercial and financial perspectives, in order to ensure its success upon commercialisation.

Keywords: spheroid,micro tumour,chemotheraphy drug response,cancer